Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.
Summary
- Buy Price: $12.50 or better.
- Sell Price: TradersPro Sell Signal.
- Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases.
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system.
Want more? Well, if you really want to retire early, this is what the top stock investors do - Click Here
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
